214 related articles for article (PubMed ID: 20148091)
1. Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India.
Satyanarayana K; Srivastava S
Open AIDS J; 2010 Jan; 4():41-53. PubMed ID: 20148091
[TBL] [Abstract][Full Text] [Related]
2. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
3. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.
Waning B; Diedrichsen E; Moon S
J Int AIDS Soc; 2010 Sep; 13():35. PubMed ID: 20840741
[TBL] [Abstract][Full Text] [Related]
4. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
[TBL] [Abstract][Full Text] [Related]
5. Trends and economic stress: a challenge to universal access to antiretroviral treatment in India.
Dhamija P; Bansal D; Medhi B
Curr HIV Res; 2009 Jul; 7(4):410-7. PubMed ID: 19601776
[TBL] [Abstract][Full Text] [Related]
6. HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?
Chien CV
PLoS One; 2007 Mar; 2(3):e278. PubMed ID: 17372625
[TBL] [Abstract][Full Text] [Related]
7. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
[TBL] [Abstract][Full Text] [Related]
8. A method for understanding generic procurement of HIV medicines by developing countries with patent protection.
Beall RF; Attaran A
Soc Sci Med; 2017 Jul; 185():118-126. PubMed ID: 28578209
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
Halliburton M
Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
[TBL] [Abstract][Full Text] [Related]
10. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals.
Babovic S; Wasan KM
J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678
[TBL] [Abstract][Full Text] [Related]
11. The UNITAID Patent Pool Initiative: Bringing Patents Together for the Common Good.
Bermudez J; 't Hoen E
Open AIDS J; 2010 Jan; 4():37-40. PubMed ID: 20309404
[TBL] [Abstract][Full Text] [Related]
12. Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics.
Dionisio D; Racalbuto V; Messeri D
Open AIDS J; 2010 Jan; 4():70-5. PubMed ID: 20200604
[TBL] [Abstract][Full Text] [Related]
13. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
Jain D; Darrow JJ
Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
[TBL] [Abstract][Full Text] [Related]
14. Taking the fight to their realm: the role of patent oppositions in the struggle for access to medicines.
Park C
HIV AIDS Policy Law Rev; 2006 Dec; 11(2-3):84-5. PubMed ID: 17375435
[TBL] [Abstract][Full Text] [Related]
15. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?
Beck EJ; Mandalia S; DongmoNguimfack B; Pinheiro E; 't Hoen E; Boulet P; Stover J; Gupta A; Juneja S; Habiyambere V; Ghys P; Nunez C
Glob Health Action; 2019; 12(1):1586317. PubMed ID: 30983547
[TBL] [Abstract][Full Text] [Related]
16. The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.
Waning B; Diedrichsen E; Jambert E; Bärnighausen T; Li Y; Pouw M; Moon S
BMC Pediatr; 2010 Oct; 10():74. PubMed ID: 20950492
[TBL] [Abstract][Full Text] [Related]
17. Companies reduce prices for HIV drugs in developing countries.
Gottlieb S
Bull World Health Organ; 2000; 78(6):862. PubMed ID: 10916926
[TBL] [Abstract][Full Text] [Related]
18. An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012.
Lee JSF; Sagaon Teyssier L; Dongmo Nguimfack B; Collins IJ; Lallemant M; Perriens J; Moatti JP
BMC Pediatr; 2016 Mar; 16():41. PubMed ID: 26979974
[TBL] [Abstract][Full Text] [Related]
19. Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
Hoen E'; Berger J; Calmy A; Moon S
J Int AIDS Soc; 2011 Mar; 14():15. PubMed ID: 21439089
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
